ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
3.290
-0.250 (-7.06%)
At close: Dec 5, 2025, 4:00 PM EST
3.390
+0.100 (3.04%)
After-hours: Dec 5, 2025, 7:06 PM EST
ADC Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for ADC Therapeutics stock ranges from a low of $5.00 to a high of $10. The average analyst price target of $7.60 forecasts a 131.00% increase in the stock price over the next year.
Price Target: $7.60 (+131.00%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 16, 2025.
Analyst Ratings
The average analyst rating for ADC Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +112.77% | Oct 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +203.95% | Aug 13, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +51.98% | Jun 20, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $7 → $10 | Strong Buy | Maintains | $7 → $10 | +203.95% | Jun 13, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +143.16% | May 15, 2025 |
Financial Forecast
Revenue This Year
78.18M
from 70.84M
Increased by 10.36%
Revenue Next Year
81.20M
from 78.18M
Increased by 3.87%
EPS This Year
-1.44
from -1.62
EPS Next Year
-1.13
from -1.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 81.5M | 96.6M | ||||
| Avg | 78.2M | 81.2M | ||||
| Low | 74.3M | 67.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.0% | 23.6% | ||||
| Avg | 10.4% | 3.9% | ||||
| Low | 4.8% | -13.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.41 | -0.88 | |
| Avg | -1.44 | -1.13 | |
| Low | -1.45 | -1.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.